Literature DB >> 8811343

HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection.

A Beretta1, L Furci, S Burastero, A Cosma, M E Dinelli, L Lopalco, C DeSantis, G Tambussi, E Carrow, S Sabbatani, M Clerici, A Lazzarin, A G Siccardi.   

Abstract

A growing number of reports indicates that certain groups of individuals who almost certainly have been exposed to human immunodeficiency virus (HIV), yet continue to exhibit no signs or symptoms of infection, often have subtle evidence of specific immunity. We studied such a high-risk (HR) cohort of persistently seronegative individuals with histories of long-term sexual exposure to an HIV-infected partner to look for evidence of both humoral and cellular immunity that might have been induced by exposure to the virus. Twenty-three heterosexual and four homosexual monogamous couples with discordant HIV status were included in the study. Twelve of the HR partners were studied for in vitro stimulation of peripheral blood mononuclear cells (PBMC) by HIV envelope-derived peptides. All 12 responded overwhelmingly to a peptide containing the fifth conserved region of gp120. By generating and cloning T cell lines specific for this peptide, we concluded that in these individuals the T cell response to the envelope is mainly focused on the carboxy-terminus region of gp120 and is characterized by an oligoclonal expansion of CD4+ T cells expressing the same TCR Eighteen HR partners and 37 HIV-1 seropositive subjects were tested for the presence of anti-CD4 antibodies (anti-CD4 Abs) using a recombinant CD4-based enzyme-linked immunosorbent assay (ELISA). Anti-CD4 Abs were detected in eight of the HR partners (six confirmed by Western blot) and in nine of the HIV-1 seropositive subjects (eight confirmed by Western blot). Results from binding competition assays with a panel of monoclonal anti-CD4 Abs suggested that the anti-CD4 Abs detected in the HR partners are directed toward epitopes that are induced by gp120 binding. Twenty-seven of the HR partners were tested for the presence of antibodies that cross-react with HLA class I and gp120 (anti-HLA Abs). Anti-HLA Abs were detected in 16 of the HR partner sera and in 4/94 sera from a control population of normal healthy blood donors. Taken together, the results suggest that in some individuals with a history of long-term exposure to HIV, specific immunity may develop in the absence of overt infection. The common trigger for these responses is gp120.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8811343     DOI: 10.1016/0165-2478(96)02553-9

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  11 in total

1.  Differential regulatory T cell activity in HIV type 1-exposed seronegative individuals.

Authors:  Laura Pattacini; Pamela M Murnane; Erin M Kahle; Michael J Bolton; Jeffrey J Delrow; Jairam R Lingappa; Elly Katabira; Deborah Donnell; M Juliana McElrath; Jared M Baeten; Jennifer M Lund
Journal:  AIDS Res Hum Retroviruses       Date:  2013-07-30       Impact factor: 2.205

2.  Epigenetic control of IRF1 responses in HIV-exposed seronegative versus HIV-susceptible individuals.

Authors:  Ruey-Chyi Su; Aida Sivro; Joshua Kimani; Walter Jaoko; Francis A Plummer; T Blake Ball
Journal:  Blood       Date:  2011-01-03       Impact factor: 22.113

Review 3.  Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN).

Authors:  C Tomescu; S Abdulhaqq; L J Montaner
Journal:  Clin Exp Immunol       Date:  2011-03-17       Impact factor: 4.330

4.  Innate activation of MDC and NK cells in high-risk HIV-1-exposed seronegative IV-drug users who share needles when compared with low-risk nonsharing IV-drug user controls.

Authors:  Costin Tomescu; Kelly E Seaton; Peter Smith; Mack Taylor; Georgia D Tomaras; David S Metzger; Luis J Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2015-03-01       Impact factor: 3.731

5.  Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus.

Authors:  J Richardson; A Moraillon; F Crespeau; S Baud; P Sonigo; G Pancino
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits.

Authors:  Nancy L Tumba; Gavin R Owen; Mark A Killick; Maria A Papathanasopoulos
Journal:  Vaccine X       Date:  2022-09-30

7.  An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques.

Authors:  Jennifer A Schwartz; Ilia Prado; Johnathan Misamore; Deborah Weiss; Jesse Francis; Ranajit Pal; Maria Huaman; Anthony Cristillo; George K Lewis; Robert C Gallo; Anthony L DeVico; Timothy R Fouts
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

Review 8.  Mucosal correlates of protection in HIV-1-exposed sero-negative persons.

Authors:  Ruizhong Shen; Phillip D Smith
Journal:  Am J Reprod Immunol       Date:  2014-01-16       Impact factor: 3.886

9.  Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals.

Authors:  Adam J Ritchie; Suzanne L Campion; Jakub Kopycinski; Zoe Moodie; Z Maggie Wang; Kruti Pandya; Stephen Moore; Michael K P Liu; Simon Brackenridge; Kristin Kuldanek; Kenneth Legg; Myron S Cohen; Eric L Delwart; Barton F Haynes; Sarah Fidler; Andrew J McMichael; Nilu Goonetilleke
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 10.  A novel HIV vaccine targeting the protease cleavage sites.

Authors:  Hongzhao Li; Robert W Omange; Francis A Plummer; Ma Luo
Journal:  AIDS Res Ther       Date:  2017-09-12       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.